A New Strategy Towards Improved Prostate Cancer Diagnosis and Prognosis of Disease Outcome

The Proveri approach to prostate cancer diagnosis and prognosis takes advantage of unique properties of the Prostate Tumor Microenvironment:

  • It is a rich source of prognostic and diagnostic biomarkers
  • Compared to tumor epithelial tissue it is nearly free of genetic heterogeneity
  • Extends the effective volume of diagnostic and prognostic clinical tissue biopsies


The majority of prostate cancers originate in the epithelial tissue lining the prostate glands. The surrounding tissue (stroma) reacts to the developing tumor with molecular changes (“reactive stroma”) that are measurable on the RNA expression and protein levels and can be exploited for diagnostic and prognostic tests. In contrast to tumors, which display considerable genetic heterogeneity (also more than one tumor can arise in a single prostate by different genetic mechanisms), the tumor microenvironment is genetically stable. Thus biomarkers derived from tumor surrounding stroma have a higher chance of being applicable to a broader patient population.

Approach Proveri is developing clinical assays based stroma-derived biomarkers:

  • 114 Diagnostic Biomarkers
    • Overall accuracy of tumor detection: 97%*
    •   15 Prognostic Biomarkers
      • Overall accuracy of detecting aggressive cancer: 87%*
*see the Publications Tab for supporting data
Contact info@provericorp.com
US: +1 858-736-6540 DE: +49 175-665-4307